Literature DB >> 2528579

Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM.

R H Carter1, D T Fearon.   

Abstract

Polymeric C3dg (pC3dg), having an average m.w. of approximately 400,000 and saturating complement receptor type 2 (CR2) on B lymphoblastoid cells at 1 micrograms/ml, was preincubated with tonsillar B cells for 24 h, after which anti-IgM was added and proliferation assessed by thymidine incorporation. Preculture of B cells with 0.01 to 1.0 micrograms/ml of polymerized C3dg (pC3dg) caused a dose-dependent enhancement of proliferation and accelerated entry into S phase after addition of anti-IgM. The continued presence of pC3dg during stimulation by anti-IgM was not required. pC3dg alone did not induce proliferation and preculture of B cells with C3dg monomer had no effect on the subsequent response to anti-IgM. The priming effect of pC3dg required at least 6 h and was greatest after 24 h of preculture. Preincubation with pC3dg did not lower the concentration of anti-IgM necessary for induction of proliferation, but did enhance proliferation at all concentrations above this threshold. Augmented proliferation occurred only in B cells of higher density in Percoll gradients, and neither T cells nor monocytes were required. Thus, independent interaction of CR2 with its natural ligand primes the B cell for subsequent stimulation through the Ag receptor, an effect that might synergize with the previously described CR2 function of lowering the threshold for B cell activation when crosslinked to membrane IgM.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528579

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  The role of complement in the acquired immune response.

Authors:  C H Nielsen; E M Fischer; R G Leslie
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

Review 2.  Complement receptors and the shaping of the natural antibody repertoire.

Authors:  V Michael Holers
Journal:  Springer Semin Immunopathol       Date:  2004-12-22

3.  Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.

Authors:  James M Kovacs; Jonathan P Hannan; Elan Z Eisenmesser; V Michael Holers
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

Review 4.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

Review 5.  CD19 function in central and peripheral B-cell development.

Authors:  Christopher J Del Nagro; Dennis C Otero; Amy N Anzelon; Sidne A Omori; Ravi V Kolla; Robert C Rickert
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

6.  C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro.

Authors:  Pavel A Nikitin; Eileen L Rose; Tony S Byun; Graham C Parry; Sandip Panicker
Journal:  J Immunol       Date:  2019-01-11       Impact factor: 5.422

7.  Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.

Authors:  James M Kovacs; Jonathan P Hannan; Elan Z Eisenmesser; V Michael Holers
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

8.  The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.

Authors:  E H Olesen; A A Johnson; G Damgaard; R G Leslie
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

9.  T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE).

Authors:  E Levy; J Ambrus; L Kahl; H Molina; K Tung; V M Holers
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

10.  Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2.

Authors:  A W Griffioen; G T Rijkers; P Janssens-Korpela; B J Zegers
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.